Overview

Intensified Rituimab Prephase Before FCR in Untreated B-CLL

Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
Phase II, multicenter, randomized trial, exploring intensified Rituximab prephase monotherapy before standard Fludarabine-Cyclophosphamide-Rituximab FC-R regimen in previously untreated symptomatic B-cell chronic lymphocytic leukemia CLL. A Study from the Goelams GCFLLCMW intergroup
Phase:
Phase 2
Details
Lead Sponsor:
French Innovative Leukemia Organisation
Collaborator:
Roche Pharma AG
Treatments:
Cyclophosphamide
Fludarabine
Fludarabine phosphate
Rituximab
Vidarabine